Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 22

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 22
---
 AreaAldeyraReproxalapOther/UndisclosedBendaRxBendamustineOncologyMarinusGanaxalone IVCentral Nervous SystemOhara PharmaceuticalsJPH203OncologyOptheaOPT-302OphthalmologyOutlook TherapeuticsONS-5010Other/UndisclosedPalvellaQtorin rapamycinOther/UndisclosedSermonixLasofoxifeneOncologySQ InnovationCE-FurosemideCardiovascular DiseaseSunshine LakeVilazodoneCentral Nervous System

12

Phase 2Partner NameProgramTherapeutic AreaAgenusBot/BalOncologyAnebuloANEB-001Central Nervous SystemCorvusCiforadenantOncologyCurXCE-TopiramateCentral Nervous SystemPhoenix TissuePTR-01Genetic DiseaseSatoSB206 (Japan)Infectious DiseaseVeronaEnsifentrine (nebulizer)Non-Cystic Fibrosis BronchiectasisVeronaEnsifentrine + LAMA (Nebulizer)COPDVikingVK5211Inflammatory/MetabolicVikingVK2809Inflammatory/MetabolicXi'an XintongMB07133OncologyPhase 1Partner NameProgramTherapeutic AreaArcellxACLX-001OncologyArcellxACLX-002OncologyBelotecaCE-ZiprasidoneCentral Nervous SystemChina Resources Double CraneCX2101ACOVID 19InvIOsAPN401OncologyJazzJZP-341Long Acting Erwinia AsparaginaseJupiter Biomedical ResearchVirightOncologyMerckV117PneumococcalNucorionNUC-1010Infectious DiseaseUroGenUGN-301OncologyVaxxasNanopatchInfectious DiseaseVikingVK-0214Genetic Disease

Summary of selected programs available for license

In addition to ZELSUVMI, discussed above, we have a number of unpartnered programs focused on a wide-range of potential indications or diseases with the potential for further development or licensing:

ProgramDevelopment StageTargeted Indication or DiseaseCE-IohexolPhase 2DiagnosticsLuminespib/Hsp90 InhibitorPhase 2OncologyCE-Sertraline, Oral ConcentratePhase 1DepressionCCR1 AntagonistPreclinical